The immunogenicity of adenovirus (Ad) vectors is enhanced by virus-specific memory immune responses present in most individuals as a result of past exposure to these ubiquitous pathogens. We previously identified the first human T-cell epitope from the major capsid protein hexon, H910-924, and found that it is highly conserved among different Ad serotypes. Memory/effector T-cell responses to H910-924 were detected in 14 of 18 (78%) healthy adults by an interferon-g ELISPOT assay. Hexon peptide-specific CD4 Tcell lines were generated from three HLA-typed donors and analyzed using a panel of HLA homozygous B-cell lines and monoclonal antibodies to HLA class II loci. These studies reveal that the hexon epitope is restricted by HLA DP4, a class II allele present in 75% of the population. Analysis of overlapping peptides and peptides with single residue mutations identified a HLA DP4-binding motif. Additionally, antibodies to the hexon peptide were detected in all donor sera by dot blot assay and ELISA. Therefore, most individuals exhibit both memory B-and T-cell responses to this highly conserved epitope on hexon, an obligate component of all Ad vectors, including 'gutted' vectors. These data suggest that current strategies for the use of Ad gene therapy vectors will not evade memory immune responses to Ad.
Introduction
Although adenoviruses (Ads) have considerable potential as gene therapy vectors for a broad range of applications, their immunogenicity poses a serious obstacle to both efficacy and safety. In animal models, Ad vectors induce acute inflammatory responses, followed 2-3 weeks later by virus-specific T-cell responses that destroy vector-infected cells. 1, 2 In human studies, these responses are amplified because nearly all individuals have been exposed to multiple common lower Ad serotypes in childhood and retain virus-specific immune responses. 3 Very little is known about human cellular immune responses against Ads, in contrast to virus-specific antibody responses. Ad-specific T cells are crucial for recovery from natural Ad infections, because infections are more severe and sometimes fatal in patients with cellular immune dysfunction. 4, 5 We previously documented the presence of virus-specific proliferative T-cell responses in peripheral blood mononuclear cells (PBMC) from nearly all healthy adults. 6 Moreover, in contrast to serotype-specific neutralizing antibodies, we detected Tcell responses that cross-react between serotypes. Smith et al 7 have also detected Ad-specific cytotoxic T cells (CTL) that recognize multiple serotypes.
The first human T-cell epitope from Ad, located in the major capsid protein hexon, H910-924, was recently identified in this lab. 8 Responses to the hexon peptide were detected in PBMC from nine of 12 healthy adults by an interferon-g (IFN-g) ELISPOT assay and determined to be mediated by CD4 T cells. Moreover, this epitope was found to be highly conserved among different human Ad serotypes, and analysis of the X-ray crystallography structure revealed that it is located in a crucial b-pleated sheet structure that helps form the base of the hexon molecule. 9 The purposes of this study were to confirm the broad reactivity of this CD4 T-cell epitope and to identify the HLA restricting element(s). Because H910-924 was recognized by most donors tested, and donor HLA typing revealed diverse class II DR and DQ antigens, the initial hypothesis was that it is a promiscuous epitope restricted by multiple class II antigens. However, analysis of peptide-specific T-cell lines (TCL) and donor HLA DP typing reveals that HLA DP4, the most common class II allele in the general population, is the restricting element. Additionally, antibodies specific for the hexon peptide were identified in all donor sera. These data indicate that this highly conserved hexon sequence contains both T-and B-cell epitopes recognized by a majority of individuals.
Results

PBMC from most healthy adults recognize H910-924
PBMC from an expanded panel of 18 healthy adults were tested for responses to H910-924 using the highly sensitive, quantitative IFN-g ELISPOT assay as previously described. Ad-infected cell lysates (Ad antigen) and uninfected cell lysates (control antigen) were used as positive and negative controls, respectively. A representative assay from one donor is shown in Figure 1 . Memory/effector T-cell responses to H910-924 were detected from 14 of 18 healthy adults (78%) with a mean frequency of 56 per 10 6 PBMC (range 20-158). In comparison, all 18 donors exhibited T-cell responses to whole Ad with a mean frequency of 175 per 10 6 PBMC (range 34-439). These data confirm that a majority of individuals recognize the highly conserved CD4 T-cell epitope H910-924 on the Ad capsid protein hexon.
Hexon peptide-specific TCL is restricted by HLA DP4
A peptide-specific CD4 TCL was prepared from donor 3 PBMC (A33, B44, B56, DR7, DQ2, DR15, DQ6, DP4) as described under Materials and methods. In order to identify the class II restricting elements for the H910-924 epitope, the TCL was tested for responses to peptide presented by a panel of HLA homozygous B-lymphoblastoid cell lines (B-LCL) as antigen-presenting cells (APC). Peptide-loaded and mock-loaded APC were incubated overnight with the TCL and responses measured by the IFN-g ELISPOT assay (Figure 2a) . The TCL exhibited a specific response to peptide presented by autologous B-LCL, but did not recognize the HLAmismatched BM16 (A2, B18, DR12, DQ3, DP2) loaded with peptide. The HLA DR7, DQ2-matched B-LCL Mou (A29, B44, DR7, DQ2, DP2) also did not present peptide. Surprisingly, the TCL recognized peptide presented by the B-LCL Boleth (A2, B75, DR4, DQ3, DP4), matched only for HLA DP4. These data indicate that HLA DP4 is a restricting element for H910-924. Additionally, the TCL recognized peptide presented by the B-LCL MGAR, which shares DR15, DQ6, and DP4 (data not shown). Because all DR15, DQ6-positive cell lines available to us were also positive for DP4, a contribution from DR15/ DQ6 could not be excluded. The TCL was incubated 3 h with HLA DP4-matched only Boleth or HLA-mismatched BM16 preloaded with 1 mM H910-924 or no peptide and cytotoxicity measured by calcein-release assay. (c) The TCL was incubated with peptide-loaded autologous B-LCL preincubated with 40 mg/ml mAb against HLA DP, DR, or DQ or media alone (E:T ratio of 10:1), and cytotoxicity was measured. The % specific lysis for targets without peptide was under 5% (data not shown).
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Hexon peptide-specific TCL kills HLA DP4-matched targets
In order to confirm the HLA DP4 restriction using another method, the donor 3 peptide-specific TCL was tested for cytotoxicity against the HLA DP4-matched only target Boleth. This CD4+ TCL was previously shown to exhibit peptide-specific cytotoxicity and to kill targets expressing hexon from a vaccinia recombinant, confirming that H910-924 is naturally processed in infected cells. HLA DP4-matched only Boleth and HLA-mismatched BM16 targets were loaded with peptide, incubated with the TCL for 3 h, and cytotoxicity measured by a calcein-release assay as described under Materials and methods. As shown in Figure 2b , the TCL exhibits specific killing of peptide-loaded HLA DP4-matched Boleth and does not recognize peptide presented by HLA-mismatched BM16 targets. These data confirm that the T-cell response to H910-924 is restricted by HLA DP4.
Peptide-specific cytotoxicity is blocked by mAb against HLA DP To further evaluate the individual contribution of HLA DP, DR, and DQ molecules to peptide presentation, monoclonal antibodies (mAbs) against HLA DR, DQ, and DP were tested for the ability to block donor 3 TCL cytotoxicity. Autologous B-LCL were loaded overnight with hexon peptide, labeled with calcein, and incubated with each mAb for 30 min at RT prior to incubation with the TCL. Cytotoxicity was measured by calcein-release assay. The mAb against HLA DP-blocked peptidespecific killing over 50%, whereas mAbs to DR and DQ did not have any measurable effect (Figure 2c ). These data indicate that donor three HLA DR and DQ alleles (DR7, DQ2, DR15, DQ6) do not significantly contribute to peptide presentation and confirm that the response to H910-924 is restricted by HLA DP4.
Peptide responders share the HLA DP4 allele; the nonresponder is negative
In order to evaluate the class II restriction for H910-924 among different donors, molecular HLA DP typing was performed on six additional donors previously typed for HLA A, B, DR, and DQ alleles. Five donors exhibit CD4 T-cell responses to the hexon peptide, and one donor does not respond to the peptide. As shown in Table 1 , which also includes donor three described above, all peptide responders share HLA DP0401, and there is no other shared DR or DQ molecule. In contrast, the peptide nonresponder (donor 7) is HLA DP4 negative (DP10, DP15). These data reveal a strong correlation between the presence of HLA DP4 and the response to the hexon peptide among different donors.
Hexon peptide-specific TCL from two other donors are restricted by HLA DP4
In order to further confirm the HLA DP4 restriction and evaluate potential contributions from other class II alleles, peptide-specific CD4 TCL were generated from PBMC from donors 2 and 4. Similar to the above results with the donor 3 TCL, donors 2 and 4 TCL both recognized peptide presented by DP4-matched only targets in the IFN-g ELISPOT assay ( Table 2) . Additionally, HLA DP4-negative targets matched for HLA DR1, DQ5, DR3, DQ2, DR7, DP2, or DP3 were unable to present peptide. These data strongly support the conclusion that H910-924 is exclusively restricted by HLA DP4.
Identification of a HLA DP4-binding motif
Next, the H910-924 epitope was analyzed for the presence of a HLA DP4-binding motif. As recently elucidated by Castelli et al 10 , the HLA DP4 peptidebinding site consists of two large aromatic pockets at positions 1 (P1) and 6 (P6) that accommodate aromatic/ hydrophobic residues such as Phe, Tyr, and Leu. In addition, there are minor anchors at positions 4 and 9 that accommodate a broader range of residues. Based on this model, the H910-924 protein sequence was found to contain two putative HLA DP4-binding motifs. In motif 1, the major P1 and P6 anchors are the 914 Leu and 919 Phe: DEPTLLYVLFEVFDV. In motif 2, the 916 Tyr and 921 Val are the P1 and P6 anchors: DEPTLLYVLFEVFDV.
In order to identify the HLA DP4-binding motif for H910-924, a panel of overlapping peptides were tested against PBMC from two different donors. Responses were quantified using the IFN-g ELISPOT assay (Table 3 , top). The 9-mer peptide H913-921 is the minimal epitope recognized by PBMC and does not contain the minor P9 anchor from either motif. This data is consistent with the analysis of the model HLA DP4 peptide Oxy 271-287 : the P1 and P6 anchors were critical for peptide binding, whereas deletion of the minor P9 anchor did not eliminate binding. 10 Deletion of the hexon peptide Cterminal 6 residues, which includes the P6 and P9 anchors from both motifs, completely eliminated the PBMC response (H910-918). Additionally, PBMC did not recognize H916-925, a peptide with a deletion of the Nterminal 6 residues that deletes the motif 1 P1 anchor but retains the entire motif 2. The absence of a T-cell response to H916-925 suggests that 914 Leu and 919 Phe are the P1 and P6 anchors, respectively. Additionally, weak responses to both the H911-920 and H915-924 peptides suggest that the P2 915 Leu and P8 921 Val may enhance the T-cell response to the hexon peptide.
Next, in order to confirm the importance of the motif 1 914 Leu and 919 Phe in interacting with HLA DP4, a panel of peptides with single Ser substitutions was tested (Table 3 , bottom). Ser substitutions were used instead of Ala substitutions because the hexon peptide is 
Hexon peptide contains a B-cell epitope
Although the hexon epitope is an internal epitope within the base of the hexon molecule and is not be predicted to be recognized by antibody, it was postulated that peptide-specific T cells might provide help to generate a B-cell response. Therefore, available sera from 12 donors, including the peptide nonresponder donor 7, were screened for antibody responses to the hexon peptide. Purified Ad5 virion was used as a positive control. In addition, a panel of 16 other available 9-mer peptides from Ad proteins hexon (6), core (1), E1A (2), and DNA polymerase (7) were tested. These peptides, which contain HLA A2-binding motifs, were previously used to screen PBMC for virus-specific T-cell responses in the IFN-g ELISPOT assay. 8 First, sera were screened for responses to Ad5 virion and Ad peptides in a dot blot assay. Antibodies to both H910-924 and H913-921 were detected from all 12 donors. All sera contained antibodies against Ad5 virion (positive control), and none of the sera reacted to the Ad E1A 111-119 peptide (negative control). In addition, sera from six of six donors tested recognized one single other hexon peptide, H511-519 (GLVDCYINL). A representative dot blot assay is shown in Figure 3a . Analysis of the Ad5 hexon X-ray crystallography structure reveals that , and core protein VII (C117-125). Ad5 virion was used as a positive control; PBS and 10% DMSO were negative controls. Antigen-specific antibodies were detected with a biotinylated goat anti-human IgG using an avidin-biotinalkaline phosphatase detection system. (b) Serum (30 ml) was preabsorbed with either an excess of denatured Ad5 virions (two doses) or no virus for 30 min at RT prior to dilution and use in the dot blot assay.
Adenovirus hexon T-cell epitope J Tang et al H511-519 is located in the extended loop domain FG1 that protrudes from the top of the molecule. 9 Therefore, H511-519 is located in a region readily accessible to antibodies. None of the 14 other Ad peptides from hexon, core, E1A, and DNA polymerase were recognized (data not shown).
Is the antibody response to the hexon peptide virusspecific? It was not possible to identify donors without Ad-specific antibody to use as negative controls, because virtually all adults have been exposed to Ads. As an alternative approach, sera were preadsorbed with excess partially denatured Ad virions in order to determine if the peptide response could be blocked. As a positive control, preadsorption inhibited the antibody response to Ad virion in the dot blot assay. Preincubation of donor sera with denatured Ad virions successfully inhibited the response to the hexon peptide (Figure 3b) .
Finally, in order to compare the antibody response to the hexon peptide and whole Ad, an ELISA was performed. As shown in Table 4 , as a positive control, sera from four of four donors reacted strongly to Ad5 virion with a mean optical density (OD) sample/cutoff ratio of 11.4 (range 6.8-14.7). As a negative control, no specific responses were detected to three other Ad peptides from core protein VII, E1A, and DNA polymerase (mean OD sample/cutoff ratio o0.5). All four sera exhibited antibody responses to both H910-924 and H913-920 with a mean OD sample/cutoff ratio of 3.1 and 2.0, respectively. Additionally, preincubation of each sera with an Ad-infected cell lysate successfully inhibited the antibody response to both hexon peptides. These data confirm that donor sera exhibit specific antibody responses to the hexon peptide.
Hexon epitope is well conserved among human and animal adenoviruses
Previously, we found that this hexon epitope was highly conserved among different human Ad serotypes. In all, 20 of 22 human serotypes have the identical H910-924 sequence or have a single conserved amino-acid change in the middle of epitope (917 Val to Leu) that does not affect T-cell recognition; the remaining two serotypes have other conservative changes in middle of epitope that, based on the known characteristics of the HLA DP4 motif, are not predicted to affect binding. Hexon sequences available from nine different animal Ads were analyzed. Hexon sequences from six animal Ads contained this highly conserved epitope, whereas the other three animal Ads had multiple differences (Table 5 ).
Discussion
We report on the detection of memory/effector CD4 T-cell responses to the Ad hexon epitope H910-924 in a majority of healthy adults (14 of 18, 78%) and identification of the HLA class II molecule DP4 as the restricting allele. The 950 amino-acid hexon molecule is the most abundant protein in the Ad virion and represents the major component of the outer protein capsid. The H910-924 epitope, located near the C-terminus within a bpleated sheet 'viral jellyroll' structure that helps form the 
a Hexon C-terminus sequences from different animal adenoviruses were compared using the Bestfit program. The residues that are distinct from the Ad5 H910-924 are listed. b H910-924 epitope: the HLA DP4-binding motif P1 and P6 anchors are underlined.
Adenovirus hexon T-cell epitope J Tang et al base of the hexon molecule, is extremely well conserved among different human Ad serotypes. Analyses of hexon peptide-specific CD4 TCL from three different donors and donor HLA class II typing document that the peptide-specific T-cell response is restricted by HLA DP4. First, each TCL recognized peptide presented by HLA homozygous B-LCL matched only for HLA DP4 in the IFN-g ELISPOT assay. In contrast, B-LCL matched for HLA DR1, DQ5, DR3, DQ2, DR7, DP2, or DP3 did not present peptide. Secondly, mAb to HLA DP specifically blocked the TCL peptidespecific response in a CTL assay, where mAbs to either HLA DR or HLA DQ had no effect. Lastly, donor HLA typing confirmed that six of six peptide responders were positive for HLA DP4 whereas the one nonresponder was negative for HLA DP4. We had originally postulated that the hexon epitope was a promiscuous peptide restricted by multiple class II HLA DR antigens based on the fact that the peptide was recognized by most donors, and HLA DR and HLA DQ typing revealed that there was no single shared allele among donors. Although an mAb to HLA DR-blocked proliferation of whole PBMC to peptide, in retrospect this inhibition was likely a nonspecific effect on whole PBMC. The present direct analysis of peptide-specific TCL, in conjunction with the donor HLA DP typing data, clearly documents that HLA DP4, not HLA DR, is the restricting element.
The fact that HLA DP4 is the most common class II allele with an antigenic frequency of 75% in the general population helps explain the broad reactivity of the hexon epitope. 11 Although the currently known HLA-DP alleles include 17 a-chain alleles and 86 b-chain alleles, the HLA DP4 specificity is by far the most freqent in the general population. HLA DP4 consists of two molecules, DP401 (DPA1*0103/DPB1*0401) and the less common DP402 (DPA1*0103/DPB1*0402) that differs from DP401 by only 3 aa residues. 12 Castelli et al have documented that the HLA DP4 peptide-binding site contains two large aromatic pockets that accommodate major hydrophobic/aromatic anchor residues at P1 and P6; there are also two minor anchors at P4 and P9. In addition, DP401 and DP402 exhibit very similar patterns of recognition, the major difference being that DP402 accommodates a wider range of residues at P4. Therefore, H910-924 is predicted to bind to both HLA DP401 and DP402.
Further analysis of the hexon peptide reveals a motif consistent with the HLA DP4-binding motif described by Castelli et al. 10 Comparison of PBMC responses to a panel of overlapping peptides and single residue mutations in the IFN-g ELISPOT assay identified Leu 914 and Phe 919 as the major anchors at P1 and P6, respectively. Competition studies confirmed that peptides with Ser substitutions at either P1 or P6 did not bind to HLA DP4. Additionally, analyses of overlapping peptides suggest that both the P2 915 Leu and P8 921 Val enhance the Tcell response to peptide. It is possible that these residues may either participate in binding to HLA DP4 or may contribute to recognition of the peptide-HLA DP4 complex by the T-cell receptor. However, further evaluation will require additional peptide mutations and formal binding studies.
Although HLA DP has not been as well studied as HLA DR, a number of other HLA DP4-restricted epitopes have recently been identified. Examples include the tumor antigens NY-ESO-1 and MAGE 3 and viral antigens from rabies and hepatitis B virus. [13] [14] [15] [16] The identification of HLA DP4 epitopes from viral and tumor antigens will be valuable tools because these CD4 T-cell epitopes can be recognized by a majority of the general population. For instance, dendritic cells loaded with the MAGE 3 HLA DP4 peptide have recently been shown to induce T-helper cell responses in a majority of patients with metastatic melanoma. 17 Additionally, this hexon epitope was recognized by all donor sera and thus represents a B-cell epitope. Sera from most individuals contain multiple antibodies to hexon, including serotype-specific neutralizing antibodies targeted to variable regions on the external surface of the molecule. In contrast, H910-924 is located deep within the base of the native hexon molecule where it is not accessible to antibody. Therefore, it is likely that hexon-specific T cells provide help to generate a B-cell response to this epitope after it is processed from hexon within cells. There are several other examples of sequences that are known to represent both T-and Bcell epitopes, including epitopes from Epstein-Barr virus and influenza. 18, 19 Of note, although it was postulated that the antibody response to this internal hexon epitope was generated because of the presence of peptidespecific T-cell help, sera from donor 7, the HLA DP4-negative peptide nonresponder, also contained antibody against H910-924. This data suggests that T cells specific for other hexon epitopes or other Ad proteins may provide T cell help to generate a B-cell response to H910-924.
Hexon, the major capsid protein, is an obligate component of all Ad vectors. Although most Ad vectors are E1 deleted and express little or no new hexon proteins, input virus contain abundant hexon molecules that can be presented by dendritic cells to both CD4 and CD8 T cells. 7, 20 Similarly, 'gutted' or helper-dependent Ads do not contain viral protein coding sequences but are packaged with capsid proteins. 21 Therefore, Ad-specific memory T cells from most individuals will recognize both E1-deleted and 'gutted' vectorinfected cells. Previously, we found that this hexon epitope was highly conserved among different human Ad serotypes. As another approach to evade the immune responses to Ad vectors, some investigators are developing vectors based on animal Ads, such as the chimpanzee Ad CV68 and bovine Ad3. 22, 23 Hexon sequences from six of nine animal Ads, including the chimp Ad and the bovine Ad3, contained this highly conserved epitope. Therefore, hexon peptide-specific T cells will recognize vectors based on most human as well as animal Ads.
These data highlight the need to develop new strategies to reduce the immunogenicity of Ad vectors. This study suggests that it is important to take into consideration pre-existing memory cellular immune responses to this ubiquitous human viral pathogen. In contrast to serotype-specific neutralizing antibodies, Tcell responses to conserved epitopes on hexon, such as H910-924, will not be evaded by using vectors based on different Ad serotypes. Another approach, for instance, may be to alter such conserved T-cell epitopes on hexon. Further elucidation of the human T-cell responses to Ads will be crucial to order to design safer and more efficient Ad-based vectors.
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Materials and methods
Study participants
Blood specimens were obtained from 14 healthy volunteers ages 18-65 years after written informed consent was obtained. Buffy coats from four random blood donors were obtained from the Blood Bank. The Thomas Jefferson University Institutional Review Board approved the research protocol.
Cell lines
The human epithelial carcinoma cell line A549 was maintained in DMEM supplemented with 10% fetal bovine serum (FBS), 2 mM glutamine, 100 U/ml of penicillin, and 100 mg/ml of streptomycin. B-LCL were prepared from donor PBMC as previously described. 6 The homozygous B-LCL BM16, Mou, Boleth, Lwags, MGAR, and Cox were kindly provided by D Eckels, Medical College of Wisconsin. 24 B-LCL were maintained in RPMI 1640 supplemented with 10% FBS, glutamine, penicillin, and streptomycin.
Synthetic peptides
Peptides were synthesized by Research Genetics (Huntsville, AL, USA) or Sigma (St Louis, MO, USA) using Fmoc synthesis methods and purity assayed by mass spectrometry analysis. Peptides were dissolved in dimethyl sulfoxide (DMSO) at 10 mg/ml and stored in small aliquots at À701C.
Ad antigen and virion
Ad and control antigens were prepared from the subgroup C Ad type 2-infected and uninfected A549 cell lysates as previously described. 6 Subgroup C Ad type 5 virion was purified from infected A549 cell lysates by an affinity chromatography method (Virapur, Carlsbad, CA, USA) as per the manufacturer's instructions. The virion preparation was titered by a plaque assay as previously described. 6 
HLA DP typing
Sequence-based HLA Typing for DPB1 alleles was performed on a 3100 Genetic Analyzer (ABI, Foster City, CA, USA) using reagents from Forensic Analytical Specialty Inc. (Hayward, CA, USA). Ambiguous typing combinations over exon 2 were resolved by performing additional high-resolution sequence-specific primer (SSP) tests using reagents from GenoVision (QIAGEN Co., Valencia, CA, USA).
IFN-g ELISPOT assay
PBMC were separated from heparinized whole blood or buffy coat collections using Ficoll-Hypaque density gradient centrifugation, and cells were used either fresh or thawed from cryopreserved aliquots. The IFN-g ELISPOT assay was performed as previously described, using 96-well polyvinylidene difluoride backed plates (Millipore, Bedford, MA, USA) with anti-IFN-g mAbs purchased from Mabtech (Stockholm, Sweden). 25 In all, 10 mM of each peptide was incubated with 250 000 PBMC in 100 ml RPMI supplemented with 10% pooled human AB sera (Atlanta Biologicals, Atlanta, GA, USA), 10 mM HEPES, 2 mM glutamine, 100 U/ml penicillin, and 100 mg/ml streptomycin (R10) in triplicate wells for 20 h, unless otherwise specified. Spots were detected with a biotin-avidin alkaline phosphatase conjugate.
Hexon peptide-specific TCL PBMC from each donor (4 Â 10 6 ) were suspended in 200 ml R10 and incubated with 100 mM peptide for 1 h. Cells were diluted to 2 ml with R10 and incubated in a 24-well plate at 371C in a 5% CO 2 atmosphere. After 7 days, human recombinant IL-2 (Becton Dickinson, Bedford, MA, USA) was added to a final concentration of 20 U/ml and then every 3-4 days. TCL (1 Â 10 6 per well) were restimulated with peptide-loaded, irradiated autologous PBMC (3000 rad) or B-LCL (6000 rad) (2 Â 10 6 per well) every 7-10 days.
CTL assay
Cytotoxicity was measured by a calcein release assay as previously described. 8 For blocking experiments, targets were preincubated with 40 mg/ml class II locus-specific mAbs against monomorphic determinants on HLA-DR (clone L243), HLA-DP (clone B7/21), and HLA-DQ (clone Ia3) (Leinco Technologies, St Louis, MO, USA) for 30 0 at RT and then added to an equal volume of effectors.
Dot blot assay
Antigens (1.5 ml each) were applied to nitrocellulose membranes (Schleicher & Schuell, Keene, NH, USA) and air-dried for 10 min. Membranes was blocked with 1% goat sera diluted in 100 mM Tris-HCl, pH 7.5, containing 0.1% Tween-20 and 0.9% NaCl (TTBS) for 30 min on a horizontal shaker. Then, each membrane was incubated with individual human sera diluted 1:100 in TTBS, 1% goat sera for 1 h and washed three times in TTBS, 5 min each. Blots were developed using an avidin DH and biotinylated alkaline phosphatase H system from Vector Laboratories (Burlingame, CA, USA) according to the manufacturer's instructions. Purified Ad5 virions, that were partially denatured by multiple freeze-thaw cycles and UV-inactivated (4.8 Â 10 10 PFU/ml), were used as a positive control. Synthetic peptides, prepared as 10 mM stocks in DMSO, were each diluted 1:10 in PBS before use. PBS and 10% DMSO (diluted in PBS) were used as negative controls.
ELISA 96-well U-bottom plates (Becton Dickson, NJ, USA) were coated with 1 mM peptide or 4.5 Â 10 8 PFU/ml. Ad virion (75 ml per well) dissolved in 0.05 M bicarbonate buffer, pH 9.6, for 20 h at 371C. Wells were washed three times with PBS containing 0.5% Tween-20 and blocked with TTBS containing 1% goat serum for 30 min at RT. Each sera, diluted 1:100 in TTBS plus 1% goat sera, was added to triplicate wells (100 ml), and plates were incubated for 2 h at RT and washed five times. Biotinylated goat anti-human IgG (Vector Laboratories, Burlingame, CA, USA) (1:100 in TTBS) was added for 30 min at RT, and plates were rinsed three times, followed by a 30 min incubation with Vectastain ABC-AP reagent and three washes. The reaction was developed with the substrate p-nitrophenyl phosphate (Vector Laboatories, Burlingame, CA, USA) for 1 h at RT, and the OD was read at 405 nm. TTBS containing 1% goat sera was used as a negative control for each run. For blocking Adenovirus hexon T-cell epitope J Tang et al studies, each sera was incubated with Ad-infected cell lysate for 30 min at RT before use in ELISA.
Ad sequences
Ad hexon protein sequences were obtained from a search of the Entrez databases on the NCBI website (http:// www.ncbi.nlm.nih.gov), and sequence comparisons were performed using the similarity search program BLAST.
Immunophenotyping
Analysis of cell surface antigens was done by two-color immunofluorescence flow cytometry using standard direct staining methods, as previously described. 8 All mAbs were purchased as fluorescein or phycoerythrin conjugates (Becton Dickinson, San Jose, CA, USA). MAb cocktails used were CD45/CD14, CD3/CD8, and CD3/ CD4. Nonspecific binding was monitored using isotypic controls.
Statistical analysis
Data from the ELISPOT assays were analyzed using a paired t-test to compare the mean number of spotforming cells (SFCs) in the triplicate control and experimental microwells. Data from the ELISA were analyzed by calculating the mean OD, standard deviation (s.d.), and the coefficient of variability (CV), defined as the ratio of s.d. to mean OD, for each sample. The OD cutoff was calculated as the mean OD of the negative control plus 3 s.d. A mean OD sample/cutoff ratio 41 was considered positive.
